Einsele, Hermann
Moreau, Philippe
Bahlis, Nizar
Bhutani, Manisha
Vincent, Laure
Karlin, Lionel
Perrot, Aurore
Goldschmidt, Hartmut
van de Donk, Niels W. C. J.
Ocio, Enrique M.
Martinez-Lopez, Joaquin
Rodríguez-Otero, Paula
Dytfeld, Dominik
Diels, Joris
Strulev, Vadim
Haddad, Imene
Renaud, Thomas
Ammann, Eric
Cabrieto, Jedelyn
Perualila, Nolen
Gan, Ryan
Zhang, Youyi
Parekh, Trilok
Albrecht, Claire
Weisel, Katja
Mateos, Maria-Victoria
Funding for this research was provided by:
Janssen Research and Development
Universidad de Salamanca
Article History
Received: 11 October 2023
Accepted: 19 January 2024
First Online: 24 February 2024
Declarations
:
: Hermann Einsele has received honoraria from Amgen, BMS, EUSA Pharma, Genesis, GSK, Janssen, Novartis, Sanofi, and Takeda, travel expenses from Amgen, EUSA Pharma, and Takeda and research funding from Amgen, Genesis, GSK, Janssen, Sanofi, and Takeda. Philippe Moreau has served in a consulting or advisory role and received honoraria from AbbVie, Amgen, Celgene, GSK, Janssen, Oncopeptides, and Sanofi. Nizar Bahlis has a consulting or advisory role with AbbVie, Amgen, BMS, Forus, GSK, Janssen, Pfizer, Sanofi, and Takeda, received honoraria from AbbVie, Amgen, BMS, Forus, Janssen, and Sanofi, has been a member of the steering committee at AbbVie, GSK, and Janssen and has received research funding from Janssen and Pfizer. Manisha Bhutani has received funding from Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene, Celularity Inc., Cerecor, Janssen, Legend Biotech, MedImmune, and Takeda. Laure Vincent has received funding from Janssen, honoraria from BMS and Janssen, travel expenses from Amgen, BMS, GSK, Janssen, Sanofi, and Takeda, and has participated on an advisory board for BMS, Janssen, and Takeda. Lionel Karlin has served in a consulting or advisory role and received honoraria from Amgen, BMS/Celgene, GSK, Janssen, Sanofi, Stemline, and Takeda, has received travel expenses from Amgen, BMS/Celgene, Janssen, Sanofi, and Takeda, and has an immediate family member employed by Laoratoira Aguettant. Aurore Perrot has received honoraria or served a consulting role with AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi, and Takeda. Hartmut Goldschmidt has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, Janssen-Cilag, Sanofi, and Takeda, received travel funding from Janssen-Cilag and Sanofi, honoraria from Amgen, BMS, Celgene, Chugai Pharma, GSK, Janssen-Cilag, Novartis, and Sanofi, research funding from Amgen, BMS, Celgene, Chugai Pharma Europe, Incyte, Janssen, Molecular Partners, MSD, Mundipharma, Novartis, and Takeda, and discloses other relationships with Amgen, Celgene/BMS, Chugai Pharma Europe, Janssen, and Sanofi. Niels WCJ van de Donk has received research support from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen Pharmaceuticals, and Novartis, and serves on advisory boards for AbbVie, Adaptive, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, Servier, and Takeda (all paid to their institution). Enrique M Ocio, Joaquin Martinez Lopez, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, Nolen Perualila, Ryan Gan, Youyi Zhang, Trilok Parekh, and Claire Albrecht are employees of Janssen and may own stock in Johnson & Johnson/Janssen. Katja Weisel has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Oncopeptides, Roche, Sanofi, and Takeda, received travel, accommodations, and/or expenses from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Takeda, honoraria from AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche/Genentech, Sanofi, and Takeda, and research funding from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Sanofi. Maria-Victoria Mateos has served in a consulting or advisory role for AbbVie, Amgen, Celgene, GSK, Janssen-Cilag, Pfizer, Regeneron, Roche/Genentech, and Takeda, and received honoraria from AbbVie/Genentech, Amgen, Celgene, GSK, Janssen-Cilag, Sanofi, and Takeda.
: Data analyzed in this study were received from the MonumenTAL-1, LocoMMotion, and MoMMent studies. MonumenTAL-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol (Supplementary Materials Tables InternalRef removed–S3). The LocoMMotion and MoMMent studies were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee/institutional review board at each center approved the study protocol.